Scholarlink

<p>Gastrointestinal (GI) inflammation is a predominant toxic side effect of cisplatin therapy in oncology patients. 6-Shogaol, among the most effective components derived from ginger, is effective in reducing inflammation, but its inhibitory effects on cisplatin-induced GI inflammation are unknown. This study investigates whether 6-shogaol control of cisplatin-induced GI inflammation is associated with the mTOR/TFEB-mediated autophagy-lysosomal pathway. GI inflammation was assessed by H&amp;E staining and ELISA, while network pharmacology and molecular docking were employed to identify potential targets and mechanisms. Furthermore, the autophagy marker LC3 was detected by immunofluorescence, and the mTOR/TFEB pathway was evaluated by Western blot. 6-Shogaol treatment exerted therapeutic efficacy on GI inflammation via improving cisplatin-triggered reduction in body weight and ameliorated inflammatory pathological injury in mice, with decreased levels of IL-1β, IL-6, and TNF-α. Mechanistically, 6-shogaol increased LC3II/Ⅰ, CTSB, and LAMP1 protein expression; decreased p62 protein expression; and improved the autophagy-lysosomal pathway. Immunofluorescence confirmed increased LC3 expression, particularly at the high dose. Network pharmacology and molecular docking suggested that mTOR is a key putative target of 6-shogaol in the prevention and treatment of GI inflammation, and 6-shogaol treatment was associated with suppressed mTOR/TFEB phosphorylation and enhanced TFEB entry into the nucleus. These findings indicate that cisplatin-induced autophagy suppression and GI inflammation correlate with dysregulated mTOR/TFEB signaling, while 6-shogaol treatment was associated with attenuated GI injury in conjunction with modulation of the putative mTOR/TFEB-mediated autophagy-lysosomal pathway.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

6-Shogaol attenuates cisplatin-induced gastrointestinal inflammation involving modulation of the putative mTOR/TFEB-mediated autophagy-lysosomal pathway

  • 期刊论文

  • 发表日期：

    2026年7月18日

查看全文
  • Wenzhuo Zhang,
  • Qingqing Liu,
  • Chenglu Yang,
  • Lei Feng,
  • Yunjing He,
  • Yujie Gao,
  • Yusu Wang,
  • Siyu Han,
  • Yarong Zhai,
  • Ke Nie

摘要

Gastrointestinal (GI) inflammation is a predominant toxic side effect of cisplatin therapy in oncology patients. 6-Shogaol, among the most effective components derived from ginger, is effective in reducing inflammation, but its inhibitory effects on cisplatin-induced GI inflammation are unknown. This study investigates whether 6-shogaol control of cisplatin-induced GI inflammation is associated with the mTOR/TFEB-mediated autophagy-lysosomal pathway. GI inflammation was assessed by H&E staining and ELISA, while network pharmacology and molecular docking were employed to identify potential targets and mechanisms. Furthermore, the autophagy marker LC3 was detected by immunofluorescence, and the mTOR/TFEB pathway was evaluated by Western blot. 6-Shogaol treatment exerted therapeutic efficacy on GI inflammation via improving cisplatin-triggered reduction in body weight and ameliorated inflammatory pathological injury in mice, with decreased levels of IL-1β, IL-6, and TNF-α. Mechanistically, 6-shogaol increased LC3II/Ⅰ, CTSB, and LAMP1 protein expression; decreased p62 protein expression; and improved the autophagy-lysosomal pathway. Immunofluorescence confirmed increased LC3 expression, particularly at the high dose. Network pharmacology and molecular docking suggested that mTOR is a key putative target of 6-shogaol in the prevention and treatment of GI inflammation, and 6-shogaol treatment was associated with suppressed mTOR/TFEB phosphorylation and enhanced TFEB entry into the nucleus. These findings indicate that cisplatin-induced autophagy suppression and GI inflammation correlate with dysregulated mTOR/TFEB signaling, while 6-shogaol treatment was associated with attenuated GI injury in conjunction with modulation of the putative mTOR/TFEB-mediated autophagy-lysosomal pathway.